Earnings Call · Q2 FY2026·2026-07-31

Q2 26EPS +5.97%·Rev n/aQ1 26EPS +3.48%·Rev n/aQ4 25EPS +1.63%·Rev n/aQ3 25EPS +3.18%·Rev n/a⚠ consensus missing

APTARGROUP, INC. ATR

Mary Skafidas — Senior Vice President, Investor Relations and Communications

Stephan Tanda — President and Chief Executive Officer

Vanessa Kanu — Executive Vice President and Chief Financial Officer

Gael Touya — CEO designate and President of Aptar Pharma

+0.1%1d on move date3d+1.7%5d+1.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ATR calls or request research access.

More ATR calls Browse calls Request research access